MyFloraDNA operates a DNA plant laboratory that utilizes CRISPR technology for precise gene editing to develop allergy-free peanuts, targeting specific allergenic compounds without altering the peanuts' natural qualities. This approach aims to significantly reduce allergy-related health incidents for millions of peanut allergy sufferers.
Funding
$970K raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Peanut allergies affect millions, and current methods to mitigate allergic reactions are often reactive rather than preventative. Traditional breeding methods are unable to precisely target and eliminate specific allergenic compounds in peanuts, leaving allergy sufferers at risk.
Solution
MyFloraDNA utilizes CRISPR gene-editing technology to develop allergy-free peanuts by precisely targeting and removing specific allergenic compounds without altering the peanut's natural qualities. This approach aims to proactively reduce allergy-related health incidents for peanut allergy sufferers. Through its subsidiary, MaxGene Bioscience, MyFloraDNA focuses on translating these genetic insights into sustainable agricultural applications. The company's technology offers a non-GMO solution that retains the natural taste and nutritional value of peanuts while making them safe for consumption by individuals with peanut allergies.
Target Audience
The primary target audience includes peanut allergy sufferers, food manufacturers, and agricultural companies seeking to produce and offer safer peanut products.
Features
- CRISPR-based gene editing to eliminate specific peanut allergens
- Non-GMO approach preserving natural peanut qualities
- Development of peanuts with reduced allergenicity
- Genetic analysis services for plant health and productivity
- Pathogen detection and DNA fingerprinting services